Second primary lung malignancy in head and neck cancer patients.
BACKGROUND
Second primary lung cancer (SPLC) is generally of poor prognosis in patients presenting with head and neck cancer.


METHODS
Between January 2000 and June 2008, 39 patients with head and neck squamous-cell carcinoma (HNSCC) patients diagnosed with SPLC were included.


RESULTS
Fourteen SPLC were classified as synchronous and 25 as metachronous. SPLC and HNSCC staging correlated (P=0.0496). Patients with metachronous tumor showed longer median overall survival than those with synchronous tumor (92.9 months versus 15.7 months; Hazard ratio (HR), 0.323; 95% CI, 0.042-0.559; P=0.0045). In the subgroup of 11 patients with SPLC diagnosed more than 5 years after HNSCC, prognosis was better (128.1 versus 29.7 months; HR, 0.288; 95% CI, 0.053-0.353; P<0.0001).


CONCLUSIONS
In the present study, in contrast to the literature, improved prognosis and survival were found in the subgroup in which SPLC developed more than 12 months after initial HNSCC diagnosis, and even more specifically in that in which SPLC developed more than 5 years after initial HNSCC diagnosis.


CONCLUSIONS
SPLC in HNSCC is generally described as unequivocally aggressive and of poor prognosis. Metachronous SPLC, however, especially when diagnosed more than 5 years after HNSCC, was clearly associated with better prognosis.
Dequanter
D
D
Service de chirurgie, CHU Charleroi, rue de Gozée 706, 6110 Montigny-le-Tilleul, Belgium. didier.dequanter@chu-charleroi.be
Shahla
M
M
Lardinois
I
I
Gilbert
O
O
Hanquet
O
O
Tragas
G
G
Van Meerhæghe
A
A
Lothaire
P
P
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D016609:Neoplasms, Second Primary / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D010039:Otorhinolaryngologic Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate